Share topline results for the EB-101 pivotal Phase 3 VIITAL study
Delivered after the deadline (34 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 31 Mar 2022
- Due
- 30 Sep 2022
- Delivered
- 3 Nov 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company anticipates topline results for the co-primary endpoints related to wound healing and pain reduction measured at 24 weeks post treatment in the third quarter of 2022.”
What we found
Evidence strength A What the grades mean
The company announced the topline results for the VIITAL study on November 3, 2022, which occurred after the third quarter 2022 deadline.
-
A Abeona Therapeutics Inc. 8-K filed 2022-11-14
“On November 3, 2022, Abeona announced positive topline data from the pivotal Phase 3 VIITAL study of investigational EB-101 in RDEB.” ✓ confirmed on the page
Market reaction: the shares moved -9.7% against the S&P 500 over the three sessions around the disclosure (11 Nov 2022 to 16 Nov 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Share
- Deliverable
- EB-101 Phase 3 VIITAL study topline results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Abeona Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ABEO-003385 · Corrections policy